HOME
Leading the way to a cure

Lupus Research Update: 2009 Volume 3

Volume 3, 2009 - Online Edition | In This Issue


Ten Extraordinary Years of Growth and Discovery >
Building on Our Advances in Genome Science >
Paving the Future with Cutting Edge Research >
Message from the President >
Where There is a WILL ... There is a Way to End Lupus >
The Face of Lupus: Fighting the Disease on Many Fronts >
Double the Impact of Your Generosity >
Supporting Our Lupus Research Update >
Shoe News: A Doctor Who is Also a Lupus Patient >
It's time to put on your Walking Shoes >
Federal Employees Make a Real Difference >

Ten Extraordinary Years of Growth and Discovery

The ALR has reached a major milestone: for ten years, we have advanced pioneering lupus investigations, achieving great progress in lupus research.

Today, lupus investigators are exploring widely diverse ideas and there are dozens of ongoing clinical trials . The ALR helped to create this environment by pursuing and supporting high-risk but promising ideas from talented researchers.

As Dr. Robert Eisenberg, one of our early grantees, says: "Although our early exploration of B cells is now widely believed to have enormous potential, there was no funding — other than from the ALR — in the preliminary stages."

Celebrating 10 Years of Progress in Lupus ResearchThe ALR also harnessed the use of new human genome advances in understanding lupus — with profound results. Through our International SLE Genetics Consortium (SLEGEN), researchers have identified 13 genes as markers for lupus. Dr. Robert Kimberly a former member of the ALR Scientific Advisory Board says, "SLEGEN offers limitless possibilities. For the first time, researchers can target their studies to these specific genes — it is a remarkable breakthrough."

Moreover, the ALR is helping to extend theoretical advances into clinical trials. Pharmaceutical company Human Genome Sciences recently reported positive results in late-stage clinical trials of their potential treatment for lupus, Benlysta. Benlysta effects the immune protein BLyS, which is a key factor in lupus. Dr. William Stohl, one of the first ALR grantees, explains, "BLyS is important to the survival and stimulation of B-cells. Today, we can precisely target it with Benlysta — an outgrowth of my early B-cell research, which was strongly supported by the ALR."

Building on the success of our outstanding scientists, the ALR looks ahead to the next 10 years, aiming to unlock the mysteries of lupus — for good.


1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software